Metabolic and Hepatobiliary Side Effects of Antiretroviral Therapy (ART)

Emergency Medicine Clinics of North America

Volumn 28, Issue 2, 2010, Pages 409-419

  Lugassy, Daniel M ^a   Farmer, Brenna M ^b   Nelson, Lewis S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Adverse drug events; HAART; Hepatobiliary; Metabolic; Side effects

Indexed keywords

ABACAVIR; AGENASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; KALETRAL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

AIDS RELATED COMPLEX; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; DRUG ERUPTION; DRUG FATALITY; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EOSINOPHILIA; FATTY LIVER; FEVER; GILBERT DISEASE; HEPATITIS; HEPATOBILIARY DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFECTION PREVENTION; INSULIN RESISTANCE; JAUNDICE; LACTIC ACIDOSIS; LEUKOPENIA; LIPODYSTROPHY; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; METABOLIC DISORDER; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL BLOOD LEVEL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG HYPERSENSITIVITY; DRUG MONITORING; EMERGENCY MEDICINE; EMERGENCY TREATMENT; HIV ASSOCIATED LIPODYSTROPHY; LIVER DISEASE; METHODOLOGY; TOXIC HEPATITIS;

ACIDOSIS, LACTIC; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG-INDUCED LIVER INJURY; DYSLIPIDEMIAS; EMERGENCY MEDICINE; EMERGENCY TREATMENT; FATTY LIVER; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER DISEASES; METABOLIC DISEASES; PANCREATITIS;

EID: 77952473321     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2010.01.011     Document Type: Review

References (45)

1. Lima V., Hogg R., Harrigan P.R., et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007, 21(6):685-692.
2. Pulvirenti J. Inpatient care of the HIV infected patient in the highly active antiretroviral therapy (HAART) era. Curr HIV Res 2005, 3(2):133-145.
3. Pulvirenti J., Muppidi U., Glowacki R., et al. Changes in HIV-related hospitalizations during the HAART era in an inner-city hospital. AIDS Read 2007, 17(8):390-394. 397.
4. Venkat A., Piontkowsky D.M., Cooney R.R., et al. Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy. Ann Emerg Med 2008, 52(3):274-285.
5. Llibre J.M., Falco V., Tural C., et al. The changing face of HIV/AIDS in treated patients. Curr HIV Res 2009, 7(4):365-377.
6. Palella F., Baker R., Moorman A., et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43(1):27-34.
7. Venkat A., Shippert B., Hanneman D., et al. Emergency department utilization by HIV-positive adults in the HAART era. Int J Emerg Med 2008, 1(4):287-296.
8. Puoti M., Nasta P., Gatti F., et al. HIV-related liver disease: ARV drugs, coinfection, and other risk factors. J Int Assoc Physicians AIDS Care 2009, 8(1):30-42.
9. Nunez M., Martn-Carbonero L., Moreno V., et al. Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Res Hum Retroviruses 2006, 22(9):825-829.
10. Hughes C.A., Foisy M.M., Dewhurst N., et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother 2008, 42(3):387-396.
11. Kottilil S., Polis M., Kovacs J. HIV infection, hepatitis C infection, and HAART: hard clinical choices. JAMA 2004, 292(2):243-250.
12. Nunez M., Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005, 28(1):53-66.
13. Cote H.C., Brumme Z.L., Craib K.J., et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002, 346(11):811-820.
14. Goldsmith D.R., Perry C.M. Atazanavir. Drugs 2003, 63(16):1679-1693. [discussion: 1694-5].
15. Havlir D.V., O'Marro S.D. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis 2004, 38(11):1599-1604.
16. Plosker G.L., Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999, 58(6):1165-1203.
17. Lankisch T.O., Behrens G., Ehmer U., et al. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy-an extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol 2009, 50(5):1010-1018.
18. Bonfanti P., Capetti A., Riva P., et al. Hypersensitivity reactions during antiretroviral regimens with protease inhibitors. AIDS 1997, 11(10):1301-1302.
19. Sheffield L.J., Phillimore H.E. Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev 2009, 30(2):55-65.
20. Herman J.S., Easterbrook P.J. The metabolic toxicities of antiretroviral therapy. Int J STD AIDS 2001, 12(9):555-562. [quiz 563].
21. Miller K.D., Cameron M., Wood L.V., et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000, 133(3):192-196.
22. Brinkman K., Smeitink J.A., Romijn J.A., et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999, 354(9184):1112-1115.
23. Calza L., Manfredi R., Chiodo F. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr 2005, 24(1):5-15.
24. Tan D., Walmsley S., Shen S., et al. Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors. HIV Clin Trials 2006, 7(3):107-115.
25. Lactic Acidosis International Study Group Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007, 21(18):2455-2464.
26. Manfredi R., Calza L. HIV infection and the pancreas: risk factors and potential management guidelines. Int J STD AIDS 2008, 19(2):99-105.
27. Moore R.D., Keruly J.C., Chaisson R.E. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 2001, 15(5):617-620.
28. Moore R.D., Fortgang I., Keruly J., et al. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med 1996, 101(1):34-40.
29. Schindzielorz A., Pike I., Daniels M., et al. Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clin Infect Dis 1994, 19(6):1076-1083.
30. Arenas-Pinto A., Grant A.D., Edwards S., et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 2003, 79(4):340-343.
31. Guaraldi G., Squillace N., Stentarelli C., et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008, 47(2):250-257.
32. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-F58.
33. Dube M.P., Johnson D.L., Currier J.S., et al. Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350(9079):713-714.
34. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004, 350(12):1220-1234.
35. Flexner C. HIV-protease inhibitors. N Engl J Med 1998, 338(18):1281-1292.
36. Lumpkin M. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus June 11, 1997, Public Health Advisory, Rockville (MD). FDA (Ed.).
37. Noor M.A., Seneviratne T., Aweeka F.T., et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16(5):F1-F8.
38. Murata H., Hruz P.W., Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275(27):20251-20254.
39. Zhang S., Carper M.J., Lei X., et al. Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion. Am J Physiol Endocrinol Metab 2009, 296(4):E925-E935.
40. Kaul D.R., Cinti S.K., Carver P.L., et al. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999, 19(3):281-298.
41. Fung H.B., Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 2004, 26(3):352-378.
42. Veronese L., Rautaureau J., Sadler B.M., et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000, 44(4):821-826.
43. Friis-Moller N., Sabin C.A., Weber R., et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349(21):1993-2003.
44. Brown T.T. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab 2008, 93(8):2937-2945.
45. D'Silva M., Leibowitz D., Flaherty J.P. Seizure associated with zidovudine. Lancet 1995, 346(8972):452.